List view / Grid view
Topline results from a Phase III study in NSCLC suggest…
Topline results from a Phase III study in NSCLC suggest that Rybrevant® and lazertinib could advance treatment beyond tyrosine kinase inhibitor (TKI) monotherapy.
Accelerated US approval of a first-in-class bispecific antibody (BsAb) therapy…
Accelerated US approval of a first-in-class bispecific antibody (BsAb) therapy offers a new option for a difficult-to-treat blood cancer.
Approval for Janssen’s talquetamab to treat relapsed/refractory multiple myeloma has…
Approval for Janssen’s talquetamab to treat relapsed/refractory multiple myeloma has been submitted to the European Medicines Agency.
